Correlation of Serum Gamma Glutamyl Transferase and Prostate Specific Antigen Level in Patients with Prostate Disorders

Authors

  • Mehreen Aftab Khan Department of Chemical Pathology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Ayesha Hafeez Department of Chemical Pathology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Muhammad Younas Department of Chemical Pathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Syeda Binte Zahra Rizvi Department of Hematology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Waqas Hanif Department of Chemical Pathology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Syed Hurr Department of Surgery, Nishtar Medical University, Multan Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i1.8094

Keywords:

Benign prostatic hyperplasia (BPH), Gamma glutamyl transferase, Prostate specific antigen, Prostate density, “American Urological Association” (AUA) score.

Abstract

Objective: To correlate gamma-glutamyl transferase, prostate-specific antigen, and prostate-specific antigen density with ultrasound findings, including prostate-specific antigen volume and density, in patients with prostate disorders and to compare differences between Gamma-GT, prostate-specific antigen levels, and density based upon “American Urological Association” score questionnaire groups.

Study Design: Cross sectional study.

Place and Duration of Study: Combined Military Hospital Multan, Pakistan, from Nov 2019 to Dec 2021.

Methodology: We measured prostate indices, including prostate-specific antigen, prostate-specific antigen volume, prostate-specific antigen size, and prostate-specific antigen density, through biochemical measurements and ultrasound examination in a patient population [(n=336) and (age 45-90 years)] randomly after several exclusions that could have affected the results of gamma-glutamyl transferase in known prostate disorders.

Results: Gamma-glutamyl Gamma-glutamyl indices showed a low correlation with prostate-specific antigen levels (p-value= 0.170), ultrasound measures of the prostate gland (p-value=0.088), and derived indices incorporating prostate-specific antigen results (p-value=0.025). PSA showed moderate to higher correlation with Alkaline phosphatase (r=0.422, p<0.001), gamma glutamyl transferase (r=0.170, p=<0.001), PSA volume (r=0.513, p=<0.001), prostate gland size (r=0.520, p=<0.001) and PSA density (r=0.754, p=<0.001). Statistical analysis for various biochemical parameters and PSA measures between groups formulated based on prostate size and the AUA score system was not statistically significant.

Conclusion: Prostate derived ultrasound measures and PSA density showed a higher correlation with PSA. Gamma glutamyl transferase may not help depict prostate gland disease.

Downloads

Download data is not yet available.

References

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1): 9-29.

https://doi.org/10.3322/caac.21208

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 319(18): 1914-1931.

https://doi.org/10.1001/jama.2018.3712

Persaud H, Yuan J, Afable A, Bruno DM. Barriers to Prostate Cancer Screening Among Indo-Guyanese. J Community Health 2021; 46(3): 591-596.

https://doi.org/10.1007/s10900-020-00926-5

Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A, et al. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev 2014; 15(22): 9575-9578.

https://doi.org/10.7314/apjcp.2014.15.22.9575

Saad F, Lipton A. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. CurrOpin Support Palliat Care 2010; 4(3): 127-134.

https://doi.org/10.1097/SPC.0b013e32833ac6d6

Hammerich KH, Donahue TF, Rosner IL, Cullen J, Kuo HC, Hurwitz L, et al. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Urol Oncol 2017; 35(7): 460.e21-460.e28.

https://doi.org/10.1016/j.urolonc.2017.02.001

Chen JT, Kotani K. Serum γ-glutamyl transpeptidase and oxidative stress in subjectively healthy women: an association with menopausal stages. Aging Clin Exp Res 2016; 28(4): 619-24.

https://doi.org/10.1007/s40520-015-0460-y

Drabovich AP, Saraon P, Drabovich M, Karakosta TD, Dimitromanolakis A, Hyndman ME, et al. Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyl transferase 4 in Seminal Plasma of Prostate Cancer Patients. Mol Cell Proteomics 2019 ;18(9): 1807-1823. https://doi.org/10.1074/mcp.RA119.001612

Kunutsor SK, Laukkanen JA. Gamma-glutamyl transferase and risk of prostate cancer: Findings from the KIHD prospective cohort study. Int J Cancer 2017; 140(4): 818-824.

https://doi.org/10.1002/ijc.30511

Bosco C, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, et al. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort. BMC Cancer 2018; 18(1): 205.

https://doi.org/10.1186/s12885-018-4111-5

Cheung BM, Ong KL, Tso AW, Cherny SS, Sham PC, Lam TH Gamma-glutamyl transferase level predicts the development of hypertension in Hong Kong Chinese. Clin Chim Acta 2011; 412(15-16): 1326-1331.

https://doi.org/10.1016/j.cca.2011.03.030

Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta 2018; 476: 130-138.

https://doi.org/10.1016/j.cca.2017.11.026

Barry MJ, Fowler FJ Jr, O'leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK; Measurement Committee of the American Urological Association. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 2017; 197(2S): S189-S197.

https://doi.org/10.1016/j.juro.2016.10.071

Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 2018; 21(1): 57-63.

https://doi.org/10.1038/s41391-017-0024-7

Arjunlal TS, Deepanjali S, Manikandan R, Medha R. Frequency and clinical significance of prostatic involvement in men with febrile urinary tract infection: a prospective observational study. F1000Res 2020; 9: 617.

https://doi.org/10.12688/f1000research.24094.3

Gui-Zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol 2011; 43(2): 295-301. https://doi.org/10.1007/s11255-010-9825-5

Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P. Clarifying the PSA grey zone: The management of patients with a borderline PSA. Int J Clin Pract 2016; 70(11): 950-959.

https://doi.org/10.1111/ijcp.12883

Rao SR, Snaith AE, Marino D, Cheng X, Lwin ST, Orriss IR, et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br J Cancer 2017; 116(2): 227-236.

https://doi.org/10.1038/bjc.2016.402

Baba TT, Terashima T, Oida S. Liver-type of tissue non-specific alkaline phosphatase is induced during mouse bone and tooth cell differentiation. Arch Oral Biol 2019; 98: 32-37.

https://doi.org/10.1016/j.archoralbio.2018.10.036

Downloads

Published

28-02-2025

Issue

Section

Original Articles

How to Cite

1.
Khan MA, Hafeez A, Younas M, Rizvi SBZ, Hanif W, Hurr S. Correlation of Serum Gamma Glutamyl Transferase and Prostate Specific Antigen Level in Patients with Prostate Disorders. Pak Armed Forces Med J [Internet]. 2025 Feb. 28 [cited 2025 Mar. 28];75(1):16-20. Available from: https://pafmj.org/PAFMJ/article/view/8094